Cuauhtémoc de la Peña1, María F Gonzalez1, César González2, Joel M Salazar2, Benjamín Cruz3. 1. Department of Radiosurgery, Christus Muguerza Hospital Alta Especialidad Monterrey, Nuevo León, Mexico. 2. Department of Oncology, Christus Muguerza Hospital Alta Especialidad Monterrey, Nuevo León, Mexico. 3. Texas Tech University Health Science Center, El Paso TX USA.
Abstract
BACKGROUND AND AIM: The role of stereotactic body radiation therapy (SBRT) in the management of liver metastasis is increasing, using ablative doses with the goal of local control and ultimately improving survival. The aim of this study is to evaluate our initial results regarding local control, overall survival and toxicity in patients with liver metastases treated with this technique, due to the lack of evidence reported in Latin America. MATERIALS/ METHODS: We performed a retrospective chart review from November 2012 to June 2018 of 24 patients with 32 liver metastases. Kaplan-Meier curves were constructed for local control and overall survival. Clinical and prognostic factors were further analyzed by independent analysis. Median follow-up period was 22 months (range, 1-65 months). RESULTS: Median age was 62 years (range, 40-84 years). Colorectal carcinoma was the most common primary cancer. Overall 1-year and 2-years local control rates were 82% (95% Confidence Interval [CI], 70-98%) and 76.2% (95% CI, 45-90%), respectively. Median overall survival rate was 35 months (95%, CI 20.5-48 months). Overall 1-year and 2-year survival rates were 85.83% (95% CI, 64-99%) and 68% (95% CI, 45-84%), respectively. No acute or late grade 3 or 4 toxicity was observed during the follow-up period. CONCLUSIONS: SBRT achieves excellent local control and overall survival rates with low toxicity in patients with liver metastases. Based on our literature review, our results are consistent with larger reports. Further randomized trials are required to compare with other local therapies.
BACKGROUND AND AIM: The role of stereotactic body radiation therapy (SBRT) in the management of liver metastasis is increasing, using ablative doses with the goal of local control and ultimately improving survival. The aim of this study is to evaluate our initial results regarding local control, overall survival and toxicity in patients with liver metastases treated with this technique, due to the lack of evidence reported in Latin America. MATERIALS/ METHODS: We performed a retrospective chart review from November 2012 to June 2018 of 24 patients with 32 liver metastases. Kaplan-Meier curves were constructed for local control and overall survival. Clinical and prognostic factors were further analyzed by independent analysis. Median follow-up period was 22 months (range, 1-65 months). RESULTS: Median age was 62 years (range, 40-84 years). Colorectal carcinoma was the most common primary cancer. Overall 1-year and 2-years local control rates were 82% (95% Confidence Interval [CI], 70-98%) and 76.2% (95% CI, 45-90%), respectively. Median overall survival rate was 35 months (95%, CI 20.5-48 months). Overall 1-year and 2-year survival rates were 85.83% (95% CI, 64-99%) and 68% (95% CI, 45-84%), respectively. No acute or late grade 3 or 4 toxicity was observed during the follow-up period. CONCLUSIONS: SBRT achieves excellent local control and overall survival rates with low toxicity in patients with liver metastases. Based on our literature review, our results are consistent with larger reports. Further randomized trials are required to compare with other local therapies.
Authors: Alan W Katz; Madeleine Carey-Sampson; Ann G Muhs; Michael T Milano; Michael C Schell; Paul Okunieff Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-29 Impact factor: 7.038
Authors: Giovanni Ambrosino; Francesco Polistina; Giorgio Costantin; Paolo Francescon; Rosabianca Guglielmi; Pierluigi Zanco; Franco Casamassima; Antonio Febbraro; Giorgio Gerunda; Franco Lumachi Journal: Anticancer Res Date: 2009-08 Impact factor: 2.480
Authors: James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: A E M van der Pool; A Méndez Romero; W Wunderink; B J Heijmen; P C Levendag; C Verhoef; J N M Ijzermans Journal: Br J Surg Date: 2010-03 Impact factor: 6.939
Authors: Kyle E Rusthoven; Brian D Kavanagh; Higinia Cardenes; Volker W Stieber; Stuart H Burri; Steven J Feigenberg; Mark A Chidel; Thomas J Pugh; Wilbur Franklin; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Katharine L Aitken; Diana M Tait; Christopher M Nutting; Komel Khabra; Maria A Hawkins Journal: Acta Oncol Date: 2013-12-09 Impact factor: 4.089